Announcements Trials
Browse Landscape

Phase

Phase 1 35Phase 2 12Phase 1/2 5Phase 4 3Phase 3 3Phase NA 1Phase 2/3 1

Status

Unknown 2Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 17Thoracic 6Tumor-Agnostic 3Head & Neck 3Genitourinary 1

Conditions

Neoplasms, Second Primary 1Carcinoma, Squamous Cell 1Adenocarcinoma 1

Interventions

Drug Therapy 5Docetaxel 3Bevacizumab 3icotinib 2Vincristine 2Pemetrexed 2Misoprostol 2Genes, p53 2Gemcitabine 2Dexamethasone 2Carboplatin 2Aspirin 2pinaverium 1pentetreotide 1pembrolizumab 1pazopanib 1olaparib 1netupitant, palosentron drug combination 1nedaplatin 1lorlatinib 1durvalumab 1ceritinib 1atezolizumab 1Zoledronic Acid 1Water 1Vitamin E 1Vemurafenib 1Ultracet 1Triamcinolone 1Trastuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 4 × Docetaxel × Tumor-Agnostic × Clear all
NCT02088515 2017-03-03

Nedaplatin (Jiebaishu®) Combined With Docetaxel for Advanced Lung Squamous Cell Carcinoma

Jiangsu Simcere Pharmaceutical Co., Ltd.

Phase 4 Completed
290 enrolled
Tumor-Agnostic

Carcinoma, Squamous Cell

NCT01665417 2017-02-08

Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma

Betta Pharmaceuticals Co., Ltd.

Phase 4 Unknown
100 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT02283424 2014-11-05

Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With EGFR Gene Mutation

Chinese PLA General Hospital

Phase 4 Unknown
10 enrolled
Tumor-Agnostic

Neoplasms, Second Primary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡